# EDGAR Filing Document

**Accession Number:** 0001853816
**File Stem:** 0001493152-26-003706
**Filing Date:** 2026-1
**Character Count:** 5865
**Document Hash:** b73940cd86a5e5305be4522ae440bdd1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-003706.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001493152-26-003706

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260127

**DATE AS OF CHANGE**: 20260127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dermata Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001853816
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-268383
- **FILM NUMBER:** 26562079

**BUSINESS ADDRESS:**
- **STREET 1:** 3525 DEL MAR HEIGHTS RD., #322
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858)-223-0882

**MAIL ADDRESS:**
- **STREET 1:** 3525 DEL MAR HEIGHTS RD., #322
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**Filed Pursuant to Rule 424(b)(5)** 

**Registration No. 333-268383**

**PROSPECTUS SUPPLEMENT**

**(To Prospectus Supplements dated November 7, 2025, August 2, 2024, and June 7, 2024, to Prospectus dated November 25, 2022)**

![](form424b5_001.jpg)

**Up to $705,000**

**Common Stock**

This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as a part of our registration statement on Form S-3 (File No. 333-268383) (the "Registration Statement"), as supplemented by our prospectus supplements, dated June 7, 2024, August 2, 2024, and November 7, 2025 (collectively, the "Prior Prospectus"), relating to the offering, issuance and sale by us of our common stock, par value $0.0001 per share ("Common Stock"), from time to time that may be issued and sold under the At the Market Offering Agreement (the "Sales Agreement"), dated June 7, 2024, by and between us and H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

We are filing this prospectus supplement to amend the Prior Prospectus to update the maximum amount of shares we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our Common Stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our Common Stock having an aggregate offering price of up to $705,000 from time to time through Wainwright, which does not include the shares of Common Stock having an aggregate sales price of approximately $3,454,390 that were sold pursuant to the Prior Prospectus to date. In the event that we may sell additional amounts under the Sales Agreement and in accordance with General Instruction I.B.6, we will file another prospectus supplement prior to making such additional sales.

As of the date of this prospectus supplement, the aggregate market value of our outstanding Common Stock held by non-affiliates (the "public float"), was approximately $7,493,999, which was calculated based on 2,386,624 shares of our outstanding Common Stock held by non-affiliates as of January 23, 2026, at a price of $3.14 per share, the closing price of our Common Stock on the Nasdaq Capital Market on November 28, 2025. During the twelve (12) calendar months prior to and including the date of this prospectus supplement, we sold securities with an aggregate market value of approximately $1,792,248 pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12 calendar-month period so long as our public float remains below $75.0 million. In the event that we may sell additional amounts under the Sales Agreement, we will file another prospectus supplement prior to making such additional sales.

We are an "emerging growth company" as defined in Section 2(a) of the Securities Act and a smaller reporting company as defined under Rule 405 of the Securities Act, and as such, we have elected to comply with certain reduced public company reporting requirements. See ''Prospectus Supplement Summary— Implications of Being an Emerging Growth Company and a Smaller Reporting Company" on page S-4 of the Prior Prospectus.

Our Common Stock is listed on the Nasdaq Capital Market under the symbol "DRMA." On January 26, 2026, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $3.08 per share.

**Investing in the offered securities involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our Common Stock in "Risk Factors" beginning on page S-6 of the Prior Prospectus, and in the risks discussed under similar headings in the documents incorporated by reference in this prospectus supplement and the Prior Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.**

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

**H.C. Wainwright & Co.**

The date of this prospectus supplement is January 27, 2026